Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
03:21pm, Thursday, 09'th Nov 2023
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and mo
Novo Nordisk to discontinue Levemir insulin in U.S. market
02:43pm, Wednesday, 08'th Nov 2023
Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.
Novo Nordisk to present new cardiometabolic disease data mid-November
08:39am, Tuesday, 07'th Nov 2023
Danish drugmaker Novo Nordisk said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions fr
Why Novo Nordisk Stock Trounced the Market Today
04:44pm, Monday, 06'th Nov 2023
Two analysts separately raised their price targets on the shares. This provides even more bullish momentum for the Wegovy and Ozempic maker's stock.
Why Novo Nordisk Stock Flopped on Friday
05:14pm, Friday, 03'rd Nov 2023
An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events.
Novo Nordisk to release clinical update on star drug Wegovy
11:59am, Friday, 03'rd Nov 2023
Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next week. It was the “stunning” numbers from the pre
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
05:51am, Friday, 03'rd Nov 2023
Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.
Weight loss drug Wegovy sales fuel Novo Nordisk stock performance
02:58pm, Thursday, 02'nd Nov 2023
Novo Nordisk (NVO) stock rose after the pharmaceutical company reported strong third-quarter sales growth, fueled by its popular weight-loss drug, Wegovy. The obesity treatment generated $1.7 billion
Why Novo Nordisk Stock Is Surging Higher Today
02:15pm, Thursday, 02'nd Nov 2023
Danish pharma titan Novo Nordisk released its latest financial report Thursday morning. For the first nine months of 2023, the company posted double-digit percentage sales growth over the prior-year p
Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
01:16pm, Thursday, 02'nd Nov 2023
Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
11:26am, Thursday, 02'nd Nov 2023
Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw ga
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
10:03am, Thursday, 02'nd Nov 2023
The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.
US Wegovy Supply to Expand ‘Gradually': Novo Nordisk CEO
09:57am, Thursday, 02'nd Nov 2023
Novo Nordisk CEO Lars Fruergaard Jorgensen says starter doses of the company's weight loss medications will “be lowered somewhat” through the end of the year as the company plans to be “graduall
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
09:01am, Thursday, 02'nd Nov 2023
Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
08:24am, Thursday, 02'nd Nov 2023
Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.
